From Nasdaq:

1. With three drug platforms in development, Sarepta has more ways to treat rare diseases like Duchenne muscular dystrophy than most biotechs, including exon skipping, gene therapy, and gene editing. The company has four drugs on the market and five more in development, putting it ahead in potential breakthrough therapies.

2. Sarepta may capture a larger share of the DMD market, but it’s a slow process due to mutations in the dystrophin gene. Clinical trial recruitment and drug development will take time with a range of patient mutations to consider. Smart investors recognize these challenges.

3. Sarepta is primed for profitability, launching Elevidys and reporting operating losses of $21 million in the last quarter. With high expectations for Elevidys’ success, several upcoming developments could lead to GAAP profitability for the biotech giant. Sarepta’s viability as a business model is on the horizon for all to see.



Read more: 3 Things About Sarepta Therapeutics Every Smart Investor Knows